Excessive and inappropriate use of antibiotics is creating antibiotic resistance among affected population at present. Therefore, the urge of developing novel therapies in fighting infections is increasing. A novel, peptide based therapies for treating infections has offered various advantages in terms of stability, safety, tolerance, possesses selective nature, effective with broad spectrum of activities and mechanisms. They also protect the host from pathogenic microbes, so also referred as host defense peptides.

Peptide Based Infection Therapeutics Market – Drivers

Increase in number of pipeline drugs is expected to drive peptide based infection therapeutics market. For instance, in September 2018, BioAegis Therapeutics Inc. started clinical trials for Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in Community-Acquired Pneumonia (CAP), in Australasia and has observed reduced morbidity and mortality in over 20 infectious and non-infectious disease animal models.

Furthermore, LA Jolla Pharmaceutical Company is undergoing phase II clinical trials for LJPC-501, and is expected to complete study in April 2023. This drug can be used for treating Septic Shock.

Peptide Based Infection Therapeutics Market – Restraint

High cost of alternative techniques in manufacturing of peptide drugs to avoid peptide degradation may hamper the growth of the market. For instance, According to an article published in Biomolecule 2017, utilization of techniques such as Liposomes, PEGylation, need to develop for effective peptide drug delivery have increased the overall cost of therapy and thus restraint the growth of the market.

Peptide Based Infection Therapeutics Market – Regional Analysis

On the basis of region, the Peptide Based Infection Therapeutics Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America expected to show higher market attractiveness and domination over other regions due to new advancements in treatment such as peptide vaccines, and presence of large number of peptide manufacturing companies. In 2014-2015, AmbioPharm, Inc., a company of U.S., is manufacturing peptide based antifungals with better efficacy. This company has also expanded its manufacturing units in America and China to meet the demands.

Furthermore, high number of morbidity of infectious diseases is also driving the growth of market in U.S. For instance, According to World Health Organization (WHO) 2016 statistics, in U.S., number of new tuberculosis cases were 9,272 and number of new salmonella cases were 53,850.

Peptide Based Infection Therapeutics Market – Competitive Landscape

The key players involved in this market are Vertex Pharmaceuticals Incorporated, Merck & Co., Inc. Parchem Fine & Specialty Chemicals, AmbioPharm Inc., CoredentPharma International, GenScript, Sun Pharmaceutical Industries Ltd., Bharat Biotech, and Dr. Reddy’s Laboratories Ltd.

Peptide Based Infection Therapeutics Market – Taxonomy

By Drug

Telaprevir
Boceprevir

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

North America
Europe
Asia Pacific
Latin America
Africa
Middle East

About Author

Ghanshyam Shrivastava

Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.

Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.